Subjects expressing the glucose-6-phosphate dehydrogenase deficient phenotype experience a lower cardiovascular mortality [1]

QJM: An International Journal of Medicine

Volumn 101, Issue 2, 2008, Pages 161-163

  Cocco, P ^a   Fadda, D ^a   Schwartz, A G ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LEAD; PRASTERONE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHROMOSOME XQ; DISEASE PREDISPOSITION; DISEASE RESISTANCE; FOLLOW UP; GENE MUTATION; GENETIC TRAIT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEART INFARCTION; HUMAN; ITALY; LETTER; LONGEVITY; MASS SCREENING; MORTALITY; NONHUMAN; PHENOTYPE; PREEMPLOYMENT MEDICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMELTER; UNITED STATES;

EID: 39049106664     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm129     Document Type: Letter

References (16)

1. Cocco P, Fadda D, Atzeri S, Avataneo G, Meloni M, Flore C. Causes of death among lead smelters in relation to the glucose-6-phosphate dehydrogenase polymorphism. Occup Environ Med 2007; 64:414-6.
2. Cocco P, Todde PF, Fomera S, Manca MB, Manca P, Sias AR. Mortality in a cohort expressing the glucose-6-phosphate dehydrogenase deficiency. Blood 1998; 91:706-9.
3. Long WK, Wilson SW, Frenkel EP. Association between red cell glucose 6-phosphate variants and vascular disease. Am J Human Genet 1967; 19:35-53.
4. Sanders S, Smith DP, Thomas GA, Williams ED. A glucose-6-phosphate dehydrogenase (G6PD) splice site consensus sequence mutation associated with G6PD enzyme deficiency. Mutat Res 1997; 374:79-87.
5. Cocco P, Manca P, Dessi S. Preliminary results of a geographic correlation study on G6PD-deficiency and cancer. Toxicol Pathol 1987; 15:106-8.
6. Matsui R, Xu S, Maitland KA, Hayes A, Leopold JA, Handy DE, et al. Glucose-6-phosphate dehydrogenase deficiency decreases the vascular response to angiotensin II. Circulation 2005; 112:257-63.
7. Matsui R, Xu S, Maitland KA, Mastroianni R, Leopold JA, Handy DE, et al. Glucose-6-phosphate dehydrogenase deficiency decreases vascular superoxide and atherosclerotic lesions in apolipoprotein E(-/-) mice. Arterioscler Thromb Vasc Biol 2006; 26:910-6.
8. Raineri R, Levy HR. On the specificity of steroid interaction with mammary gland glucose-6-phosphate dehydrogenase. Biochemistry 1970; 9:2233-43.
9. Gordon G, Mackow MC, Levy HR. On the mechanism of interaction of steroids with human glucose 6-phosphate dehydrogenase. Arch Biochem Biophys 1995; 318:25-9.
10. Glei DA, Goldman N. Dehydroepiandrosterone sulfate (DHEAS) and risk for mortality among older Taiwanese. Ann Epidemiol 2006; 16 510-5.
11. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001; 86 4171-7.
12. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. J Clin Invest 1998; 82:712-20.
13. Arad Y, Badimon JJ, Badimon L, Hembree WC, Ginsberg HN. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis 1989; 9:159-66.
14. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, et al Inhibition of accelerated atherosclerosis with dehydroepiandrosterone in the heterotropic rabbit model of cardiac transplantation. Circulation 1993; 87:261-9.
15. Koenig R. Sardinia's mysterious male methuselahs. Science 2001; 291:2074-6.
16. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004; 3:171-87.